➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
AstraZeneca
Merck
Boehringer Ingelheim
Baxter

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,457,093

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,457,093
Title: Gel formulations containing growth factors
Abstract:Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, in the anterior chamber of the eye and other ophthalmic wound healing. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
Inventor(s): Cini; John K. (Bethlehem, PA), Finkenaur; Amy L. (Neshanic Station, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Application Number:08/135,230
Patent Claims:1. A pharmaceutical composition, comprising:

a) an effective wound healing amount of platelet derived growth factor (PDGF);

b) a pharmaceutically acceptable cellulose polymer; and

c) a pharmaceutically acceptable positively charged chemical species selected from the group consisting of lysine, arginine, histidine, protamine, aminoguanidine, zinc and magnesium, wherein the composition is an aqueous gel having a viscosity in the range of about 50,000 to about 150,000 cps at room temperature.

2. The composition of claim 1, wherein the PDGF is the PDGF B-B homodimer.

3. The composition of claim 1, wherein the cellulose polymer is selected from the group consisting of carboxymethylcellulose, hydroxypropylmethyl cellulose and methyl cellulose.

4. The composition of claim 1, wherein the PDGF concentration is within the range of about 1.0 ug/gram to about 1,000 ug/gram.

5. The composition of claim 1, wherein the cellulose polymer concentration is about 1.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 500,000 to about 800,000.

6. The composition of claim 1, wherein the concentration of the charged species is within the range of about 0.1% (w/w) to about 3.0% (w/w).

7. A method for healing a wound in a patient, comprising contacting the wound with a composition of claim 1.

8. A pharmaceutical composition, comprising:

a) an effective wound healing amount of human PDGF B-B homodimer;

b) carboxymethylcellulose (CMC); and

c) lysine,

wherein the composition is an aqueous gel having a viscosity in the range of about 50,000 to about 150,000 cps at room temperature.

9. The composition of claim 8, wherein the cellulose polymer concentration is about 1.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 500,000 to about 800,000.

10. The composition of claim 8, wherein the lysine concentration is within the range of about 0.1% (w/w) to about 3.0% (w/w).

11. A pharmaceutical composition, comprising:

a) an effective wound healing amount of platelet derived growth factor (PDGF);

b) a pharmaceutically acceptable cellulose polymer at a concentration in the range of about 1.5% (w/w) to about 3.0% (w/w) and having a molecular weight in the range of about 500,000 to about 800,000; and

c) a pharmaceutically acceptable positively charged chemical species selected from the group consisting of positively charged amino acids, positively charged polyamino acids and positively charged metal ions at a concentration in the range of about 0.1% (w/w) to about 3.0% (w/w),

wherein the composition is an aqueous gel having a viscosity in the range of about 50,000 to about 150,000 cps at room temperature.

12. The formulation of claim 11, wherein the chemical species is selected from the group consisting of lysine, arginine, histidine, protamine, aminoguanidine, zinc and magnesium.

Details for Patent 5,457,093

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew REGRANEX becaplermin GEL; TOPICAL 103691 001 1997-12-16 ⤷  Free Forever Trial Ethicon, Inc. (Somerville, NJ) 2012-10-10 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Harvard Business School
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.